One of the premises of targeting NPP1 as treatment for type-2-diabetes-induced insulin resistance is that the inhibition of insulin receptor and NPP1 interactions happens independently of its pyrophosphatase/phosphodiesterase activity, although the exact mechanism is still unknown (Chin et al., 2009). Here, ENPP1 is linked to type 2 diabetes mellitus.